Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabrice Andre

Showing results (61-70 of 141) with videos related to

Pageof 15
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2012
Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysisMichail Ignatiadis, Sandeep K Singhal, Christine Desmedt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancerFabrice Andre, Christos Hatzis, Keith Anderson, et al.
Nature Reviews. Clinical Oncology|March 3, 2011
Biomarker studies: a call for a comprehensive biomarker study registryFabrice Andre, Lisa M McShane, Stefan Michiels, et al.
Cancer|December 7, 2006
Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapyChafika Mazouni, Angeline Hall, Kristine Broglio, et al.
Anticancer Research|March 14, 2007
Differential immunohistochemical and biological profile of squamous cell carcinoma of the breastJulien Grenier, Jean-Charles Soria, Marie-Christine Mathieu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2023
Clinical and Genomic Characteristics of Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Following Progression on Cyclin-Dependent Kinase 4 and 6 InhibitorsXi Rao, Yongmei Chen, Julie Beyrer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2004
Breast cancer with synchronous metastases: trends in survival during a 14-year periodFabrice Andre, Khemaies Slimane, Thomas Bachelot, et al.
Breast Cancer Research and Treatment|May 1, 2007
HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancerFabrice Andre, Chafika Mazouni, Cornelia Liedtke, et al.
Cancer Medicine|March 14, 2019
Fatigue and physical activity in cancer survivors: A cross-sectional population-based studyMargarida Matias, Giulia Baciarello, Mohamed Neji, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2007
Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcomeChafika Mazouni, Florentia Peintinger, Shu Wan-Kau, et al.
Pageof 15

Showing results (61-70 of 141) with videos related to

Sort By:
Pageof 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2012
Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysisMichail Ignatiadis, Sandeep K Singhal, Christine Desmedt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancerFabrice Andre, Christos Hatzis, Keith Anderson, et al.
Nature Reviews. Clinical Oncology|March 3, 2011
Biomarker studies: a call for a comprehensive biomarker study registryFabrice Andre, Lisa M McShane, Stefan Michiels, et al.
Cancer|December 7, 2006
Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapyChafika Mazouni, Angeline Hall, Kristine Broglio, et al.
Anticancer Research|March 14, 2007
Differential immunohistochemical and biological profile of squamous cell carcinoma of the breastJulien Grenier, Jean-Charles Soria, Marie-Christine Mathieu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2023
Clinical and Genomic Characteristics of Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Following Progression on Cyclin-Dependent Kinase 4 and 6 InhibitorsXi Rao, Yongmei Chen, Julie Beyrer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2004
Breast cancer with synchronous metastases: trends in survival during a 14-year periodFabrice Andre, Khemaies Slimane, Thomas Bachelot, et al.
Breast Cancer Research and Treatment|May 1, 2007
HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancerFabrice Andre, Chafika Mazouni, Cornelia Liedtke, et al.
Cancer Medicine|March 14, 2019
Fatigue and physical activity in cancer survivors: A cross-sectional population-based studyMargarida Matias, Giulia Baciarello, Mohamed Neji, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2007
Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcomeChafika Mazouni, Florentia Peintinger, Shu Wan-Kau, et al.
Pageof 15